Julie Kim is the President of the Plasma-Derived Therapies Business Unit for Takeda Pharmaceutical Company Ltd. Ms. Kim joined Takeda in 2019 through the acquisition of Shire, where she held a number of diverse roles with increasing responsibility through her time at Baxter/Baxalta/Shire. These included roles as Global Franchise Head in different therapy areas, international market access, country and regional general management, marketing and emerging market development.
Ms. Kim represents Takeda as a Global Board Member of the Plasma Protein Therapeutics Association (PPTA) and is currently serving as Treasurer. She is also a member of the Board of Directors of Croda International Plc.
Prior to joining the industry, Ms. Kim worked in U.S. healthcare consulting.
Ms. Kim holds an MBA from the J. L. Kellogg Graduate School of Management at Northwestern University and a BA in Economics from Dartmouth College. Ms. Kim was also a 2013 Healthcare Businesswomen’s Association (HBA) Rising Star.
Ms. Kim is based in Boston and lives with her husband Matt and has two children.